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INTRODUCTION
The Lythraceae plant family consists of 25 genera with
approximately 580 species including Heimia salicifolia
(H. B. K.) Link, Heimia myrtifolia, Cham. & Schl., and
Decodon verticillatus, L.

The first crystalline lythraceae

alkaloids were described by 'Ferris ( 1), who isola ted decaline, vertaline, decinine, decamine, decodine, verticillatine, and vertine from samples of Decodon verticillatus
(Table I).

Commonly called "water oleander" or "$wamp

loose-strife," this plant is found in moderate amounts
along the Eastern seaboard of the United States and in swampy
areas near Tallahassee, Florida.

Blomster, et al. (2) re-

ported the isolation of five alkaloids from Heimia salicifolia
(lythrine, cryogenine, sinicuichine, heimine and sinine)
and noted the presence of a phenolic group, two methoxy
groups, a lactone function and aromatic unsaturation for
each of these compounds (Table I).

Douglas, et al. (3) com-

pared the alkaloidal content of Heimia salicifolia and
Heimia myrtifolia, showing that the two species have only
1

"l1diH1II' 1

Table I.

Alkaloids Isolated from Various Lythraceae Species

Alkaloid

Botanical Source

Chemical Formula

Mel tinJ?; Point

Reference

I

Lythrine

Heimia salicifolia

!

0

c 26 H29 N0 5

241-243 c
I

0

!

0

Cryogenine

Heimia salicifolia

c 26 H29 N0 5

253-255
c
I

Heimine

Heimia salicifo1ia

c 26 H29 No 6

247-~49

Nesodine
Lyfoline

Heimia salicifolia
Heimia salicifolia

2

I

c

I

c 26 H29 N0 5

190°C

c 26 H29 No 5

183°6

2
2

2,5

i

2,5

I

i

Sinicuichine

Heimia salicifolia

c 26 H29 No 5

187-i88°c

2

i

Sinine
(Lythridine)

Heimia salicifolia

c 26 H31No6

217-~19°C

2,4

Decaline

Decodon verticillatus

c 26 H31 No 5

192-194°C

1

Vertaline

Decodon verticillatus

c 26 H31No 5

194°~

1

Decinine

Decodon verticillatus

c 26 H31No 5

222°C

1

Decamine

Decodon verticillatus

c 26 H31 N0 5

222°C

1

Vertine
(Cryogenine)

Decodon verticillatus

c 26 H29 N0 5

245°(!

1

Decodine

Decodon verticillatus

C25Hl9N05

193°~:::

1

C25H27N05

312°h

I

Verticillatine Decodon verticillatus

t-:l

1
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slight variations in their alkaloidal composition.

These

authors further noted the exceedingly close botanical relationship between Heimia and Decodon; however, it was
Blomster, et al. (2)

who first published the empirical

formula for cryogenine and noted its similarity to the
Decodon alkaloid, vertine.

Zacharias, et al. (4) determined

cryogenine and vertine to be identical and established the
structure of lythrine.

The Heimia alkaloids, nesodine and

lyfoline, have been fully characterized by Appel, et al.
(5).

Heimia salicifolia (H.B.K.) Link is a small shrub which
grows in the moist highlands of Mexico and northern South
America and is used by the natives of these regions as a
multipurpose medicinal and hallucinogen.

Known as "herva

de la vida" (herb of life), "abre-o-sol" (sun opener) and
"sinicuiche" (twisted foot), the plant has a folklore reputation often bordering on the supernatural.

The ingestion

of a fermented decoction of the wilted leaves is reputed to
induce a mild euphoria consisting of visual, auditory and
perceptual distortions and a state of deja vu whereby the
partaker is able to remember with vivid clarity prenatal
incidents (6).

This fermented beverage is known in Mexico

as "sinicuichi;" however, two other intoxicating plants,
Rhynchosia praectoria, D.C. and Piscidia erythrina, L., also
share this local nomenclature (7).

-_-_ -- ---

===--=--=---=--__
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4

PHARMACOLOGICAL INVESTIGATIONS
The availability of pure alkaloids allowed Robichaud
and Malone (8) to conduct the initial pharmacological investigations of Heimia salicifolia.

These authors found that

cryogenine appeared to account qualitatively and quantitatively for the action of whole-plant extracts and they con-----------

---------------

--

- - - - - - - - - -----

-

-

--

-

-

---

------

----

eluded that cryogenine might possess "unique tranquilizing
properties" since its action was devoid of the ataxic,
blepharoptotic and autonomic side effects characteristically
seen with reserpine and the phenothiazines.

Additional work

by these researchers (9) showed cryogenine to be active in
reducing experimentally-induced anxiety in rats at doses
which produce little or no side effects.
In 1966, Jiu (10) of G. D. Searle & Co. confirmed the
central depressant activity of Heimia salicifolia extracts
and found the plant to exhibit significant anti-inflammatory
activity in two experimental models of inflammation.

Jiu's

observation, coupled with independent work at The University
of Connecticut, led Kaplan, et al. (11) to conduct the first
comprehensive anti-inflammatory evaluation of cryogenine.
These experiments showed cryogenine to be almost as potent
as phenylbutazone in preventing the development of artificially-induced inflammatory responses in rats using both
acute (carrageenan pedal edema} and chronic (Mycobacterium
butyricum adjuvant) models of inflammation.

Cryogenine's

-----------------

--
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anti-inflammatory activity appeared unrelated to any toxic
phenomena, and
two weeks

histopathological evaluations in rats after

of daily oral dosing (100 mgfkg) revealed no

lesions in any of the organs examined.
Cryogenine antagonizes several autacoids in vitro; however, this action generally appears nonspecific and can vary

Kinetic studies show cryogenine to be a non-competitive
antagonist of acetylcholine (8, 9), and extremely high concentrations are required to block nervous transmission (9).
While cryogenine is capable of reducing the pressor effects
of exogenously-administered epinephrine in the anesthetized
dog, its inability to antagonize epinephrine in the isolated
rat vas deferens strongly supports the drug's lack of involvement with adrenergic receptors (12).

Trottier and Malone

(13) found cryogenine to competitively antagonize histamine
in the isolated guinea pig uterus; however, this antagonism
becomes non-competitive when the drug concentration is increased or when the isolated terminal ileum is used.

A

similar, non-competitive antagonism of serotonin was observed
in the isolated rat uterus, and this finding correlates with
cryogenine's ability to significantly reduce serotonininduced pedal edema in the rat (11).

Cryogenine also dis-

plays a mixed antagonism against synthetic bradykinnin (14).
However, it is doubtful that its anti-inflammatory activity
can be wholly attributed to its ability to non-specifically

----------------------- ----

-------------------------------------

---

--

---

-- - - - - - - - - - - - - - - - -
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antagonize autacoids at the local level and, based on its
documented neuroleptic activity (8, 15), cryogenine's antiinflammatory activity may have a centrally-mediated component.
The ability of certain centrally-acting drugs to possess
anti-inflammatory activity is well established and related
_____ .to

_!!l~j.r_abilj. ty_0_ji)_ :i..l!hj__1Jj_t_l11ono~mi_ne .. !'e-uR_ta~e

a,nd

. __ ··-·--· __

metabolism, (ii) alter peripheral hemodynamics, (iii) interfere with ganglionic transmission, or (iv) affect the

'

pituitary-adrenal axis.
Structural and pharmacological similarities between
cryogenine and tetrabenazine led Chang and Malone (16) to
conclude that cryogenine does have a centrally-mediated
anti-inflammatory component; neither of these two compounds
affect liver glutathione stores nor alter peripheral catecholamine levels.

While cryogenine does lower mean resting

blood pressure and induce bradycardia in anesthetized dogs
(12), these activities cannot explain its effect against

chronic inflammation since it is well established that such
hemodynamic alterations can play only a minimal role.

Cryo-

genine neither fa6ilitates nor inhibits ganglionic transmission (8, 17).
Cryogenine does affect the pituitary-adrenal axis but
the nature of this involvement remains to be elucidated.
The lack of thymic, adrenal, hepatic and hematic alterations
in rats given oral doses (100 mgjkgjday) for 21 days first led

7

De Cato, et al. (18) to conclude that cryogenine's antiinflammatory activity is probably not mediated by the endogenous release of corticosteroids; however, subsequent studies
by these investigators (19) showed that crogenine's capacity
to suppress both granuloma weight and carrageenan-induced pedal
edema significantly diminished in bilaterally adrenalectomized rats.

Therefore, cryogenine's anti-inflammatory

activity may be due, in part, to the release of some adrenal
principle.

This hypothesis is supported by cryogenine's

limited effectiveness in suppressing ultraviolet-induced
erythema in guinea pigs (20), an experimental model of
inflammation that is nonresponsive to corticosteroids and
immunosuppressants.
Cryogenine's immunosuppressive activity was first
evaluated by Kosersky, et al. (21) who, impressed by the
drug's ability to inhibit both the irritant- and immuneme~iated

phases of adjuvant-induced polyarthritis (11),

quantitatively confirmed this activity and clearly differentiated the action of cryogenine from that displayed by
6-mercaptopurine.

A definitive study by Watson and Malone

(22) confirmed cryogenine's lack of immunosuppressive
capacfty at effective anti-inflammatory dose levels.
The "water diuretic" property of certain lythraceae
alkaloids was first reported by Weisbach (23) and further
explored by Weibelhaus, et al. (24), who determined that
lythrine and decinine, lythrine's dihydrocinnamic analog,

---------------

8

possessed significant activity.

The failure of earlier in-

vestigators to document this capacity may be due to the
relatively low content of lythrine found in Heimia salicifolia
Watson (26) found cryogenine to be devoid of any

(25).

significant diuretic activity in the rat.

Like prednisone,

decinine has marked anti-inflammatory activity in several
-~~-

___

~!_andard_assay§_ang__!'_e_§_j;Q:r-_~d__cl:i._l1~re~is ~il! w~ter-=lo_ad~d,

adrenalectomized rats (24).

Unlike prednisone, decinine

also blocks the anti-diuretic effects of vasopressin in both
dogs and rats.

Weibelhaus concluded:

" ... while decinine can completely block the
effects of ADH, it is probably not a specific
antagonism and the compound may cause diuresis
by acting at additional sites. Its glucocorticoidlike activity in adrenalectomized rats suggests
an involvement with basement membrane permeability."
These data support glucocorticoid-like activity for certain
of the lythraceae alkaloids and clearly demonstrate· how
relatively minor alterations in a complex molecular structure can greatly affect relative potencies and pharmacological activity.
CHEMICAL INVESTIGATIONS
There are four major groups of structurally-related
lythraceae alkaloids (Table II) and, while all groups share
the same basic skeleton, they differ in three specific
regions:

(~)

the nature of the substituents and the pat-

tern of substitution of the biphenyl ring system, (ii) the
presence of a cinnamic or dihydrocinnamic lactone, and

-~

--- - -

- - - - - - - - - ------------ --------

~~----

--
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Table II.

Structurally-Related Lythraceae Alkaloids

11

OCH

Alkaloids

Quinolizidine
Ring Fusion

3
R1
12--13

R2
C-4'

R3
C-6'

~

;::::;:

!_,

~

Lythrine
Lyfoline
Decinine
Lythridine

trans
trans
trans
trans

-CH=CH-CH=CH-CH2-CH2
-CHOH-CH2-

-OCH3
-OH
-OCH 3
-OCH 3

H
H
H
H

Cryogenine
Dec amine
Heimidine

cis
cis
cis

-CH=CH-CH2-CH2-CHOH-CH2-

-OCH3
-OCH 3
-OCH3

H
H
H

H
H
H

-OCH3
-OH
-OH

Nesodine
Deco dine
Dehydrodecodine
Sinicuichine
Vertacillatine
Dihydrovertacillatine

trans
trans
trans

-CH=CH-:-CH2-CH
-CH=CH-

-

f"f
~

~
~

cis
cis
cis

-CH=CH-CH=CH-CH 2 -cH 2 -

H
H
H

-OCH
-OH 3
--OH

- - - - - - - - ---- -----

---------

-----------

- -------- - - - - -

- - - - - - - - - - -----------

-----

-------- - - - - - - - - - - - - - - -
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(iii) the stereo-chemistry at C-10 in the quinolizidine ring.
The lythrine and cryogenine groups have oxygen substituents
at the 4 I. and 5 1 posit ions on the biphenyl nucleus while the
nesodine and verticillatine groups have oxygen substituents
at the 5 1 and

a~

positions.

These groups can be divided fur-

ther on the basis of their relative configurations at C-10
with a trans ring juncture for the nesodine and lythrine
gr,oups while the cryogenine and verticillatine groups have
a cis ring juncture (27).

Thus cryogenine and lythrine are

configurational isomers (the same molecular formula, the
same pattern of aromatic substitution, and the same configuration at the biphenyl linkage) and differ only in configuration within the quinolizidine ring system.
Ferris, et al. (28) first hypothesized that this characteristic quinolizidine ring system was derived by the conversion of lysine to delta 1 -piperidine with a subsequent transformation of the latter to isopelletierine, resulting in the
formation

o~

an asymetric center adjacent to the nitrogen

atom.

This pathway was firmly established by Spencer, et al.

(29).

Rother and Schwarting (30) found that both halves

of the .biphenyl ring system were derived from phenylalanine but the exact pathway by which phenylalanine enters
the 4-phenylquinolizidine system still remains a mystery.
Based on these reports, Rosazza, et al. (31) used a biogenetic approach in an attempt to synthesize dihydrofoline
but were unsuccessful in the oxidative coupling of the two

_ _--_-c:c=--=- -----------

~~~~~~~~~~~=~~=~-======-=-=-----

---= : _-___

:__=~~-~---

__

---_---_-_------~

:_~---
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phenyl rings.

However, two independent groups (32, 33) were

able to totally synthesize (+) decaline, a minor alkaloid
of Decodon verticillatus, which differs from the previously
mentioned alkaloids by having a biphenyl ether linkage (34).
Other alkaloids in this group include methyldecaline, largerine, vertaline and demethylvertaline.

To date, total

_______ ay_nth_e_si3_S __o_f_v_ert_a1ine_(_35_), ___ me_thyldecinine __ (36) _and methyl_-______ _
decamine (37), a biphenylquinolizidine, have been reported.
Derivatives with a carbon skeleton of 4-phenylquinolizidine
represent the fundamental structure

of all lythraceae alka-

loids (38) and are utilized as the key components in their
syntheses.

Two such phenylquinolizidines have been isolated

from 5-10 day old seedlings of Heimia salicifolia but their
absence from more mature plant samples suggests that they
serve only as biosynthetic intermediates (39).
STATEMENT OF PROBLEM
The molecular complexity of the lythraceae alkaloids
suggests that several active centers may account for their
unique pharmacological profile.

To assess these potentially

active sites, two standard models of acute inflammation
were selected for use in this present study -- the carrageenaninduced rat pedal edema assay and the croton oil-induced
mouse ear edema assay.
The inflammatory response to an injection of carrageenan,
a sulfated polysaccharide derived from Chondrus crispus

- - ---

------- - - - - - - - - - -

12
(Irish sea moss), was introduced by Winter,et al. (40) and
developed by these workers into a laboratory model for use
in the search for new anti-inflammatory agents (41, 42).
This inflammogen gives more consistent results than other
agents such as formalin, dextran and egg white (40) and
potency results correlate very well with recommended clin-

The acute inflammatory reaction which results after
the subplantar injection of carrageenan is characteristically biphasic.

The first phase begins immediately upon

injection, diminishes within one hour and accounts for 40
percent of the total edema.

The second, more accentuated

phase begins after one hour and persists through the third
hour.

Vinegar, et al. (44) determined that while aspirin

will significantly inhibit both phases of edema formation,
hydrocortisone is effective in suppressing only the second
phase of swelling.

Furthermore, the maximum suppression of

edema formation by any one agent is only 70-75 percent.
Van Arman concludes (45):
"It is interesting that the upper limit of
effectiveness of steroids and nonsteroids
is approximately the same, but the mechanisms
are different because one can achieve 100 percent inhibition by using, for example, indomethacin
and dexamethasone together.
The second model utilized in this study is the croton
oil-induced mouse ear edema assay, which was originally
developed to determine the thymolytic and antiphlogistic

-----------

-----------------------------------

----

--------

----
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activity of topically-applied corticosteroids (46).

However,

Van Arman and co-workers (47, 48) have shown that this assay
is also sensitive to several standard nonsteroidal antiinflammatory agents.

Furthermore, the relative potencies

determined by this assay correlate well with established
clinical potencies.

Since the assay is rapid, reliable, and

________ regui:r-_es only_ll!_o_d._e_s_t__aiD.Ql.l:U_t_s_o_f_ t_e_st _COll1P9tmds ,_ _it _i_s _es:pe_ci_- ____ _
ally well suited for natural products research, where it is
often difficult to obtain large amounts of pure principles
for pharmacological testing.
While the oral anti-inflammatory capacity of several of
the lythraceae alkaloids has been well documented, their
topical antiphlogistic capacity has not yet been evaluated.
Moreover, the specific function or functions of the molecule
which account for this anti-ipflammatory capacity remain
a mystery.

The present study was undertaken:

(i) to assess

the topical anti-inflammatory potential of cryogenine,
lythrine and two selected lythraceae intermediates and (ii)
to investigate the possible molecular components which produce this established, yet enigmatic anti-inflammatory effect.

- - -

--------------------

---------

MATERIALS AND METHODS

Isolation of the Alkaloids. -- Four kilograms of a methanol
extract of dried and defatted Heimia salicifolia (prepared
by W. C. Watson) were dissolved in 10 liters of 2 N HCl and
centrifugally filtered through three layers of filter paper
(Filtrax, coarse grade).

The solid residue was redissolved

in another 10 liters of 2 N HCl and continually stirred for
seven days prior to filtration in the manner described above.
The non-alkaloidal, nonpolar principles were then removed
by extracting aliquots of the combined acidified filtrates
with equal volumes of diethyl ether in a glass separatory
funnel

until the ether phase was clear and tested negative

for alkaloids.

The aqueous phase was titrated to a pH of

9.0 by 58 percent ammonium hydroxide, yielding a rust-colored
suspension.

Aliquots of this basified, aqueous fraction

were combined with equal volumes of chloroform in a glass
separatory funnel and extracted until exhausted of all
alkaloids.

The resulting 60 liters of chloroform extract

were filtered by gravity through sodium sulfate to remove
14
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residual water, then dried in vacuo at 40°C.

The resulting

dried chloroform extract (150 g) represented an approximate
4 percent yield from the methanol extract.
The dried chloroform extract was reduced to a fine
powder in a glass mortar, dissolved in a minimum amount of
absolute methanol and filtered through Whatman #1 filter
- - - - - - paper -i-n-a-Buchner-funne-1--under-suction ~- -The filtrate was - ------- ---added in increments to a warm evaporating dish containing
100 g of aluminum oxide (active neutral, activity I).

Re-

sidual methanol was evaporated at 40°C in vacuo, leaving
an admixture of chloroform extract and aluminum oxide at
a ratio of-3:2.
glass colum_n (4.5

The admixture was sprinkled onto a Bio-Rad
em~

65 em) containing 650 g of aluminum

oxide dry packed with benzene.

The chloroform extract to

aluminum oxide column packing represented a ratio of 4:1.
Elution was accomplished using the following sequence of
solvents:

(!) benzene, 100 ml; (ii) benzene:chloroform

95:5, 10 liters; (iii) benzene:chloroform 50:50, 20 liters;
and (iv) chloroform:methanol 50:50, 3 liters.
· The first three fractions were combined and reduced
by flash evaporation at 40°C in vacuo.

The resultant green-

yellow precipitate was dissolved in a minimum amount of
boiling ethyl acetate and filtered through Whatman #1 filter
paper in a Buchner funnel under suction.

The filtrate was

then heated to clarity and petroleum ether was added dropwise until the mixture turned slightly opaque.

The mixture

---------------------------------

------- -----------------
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was again heated to clarity, covered and placed in a dark
desiccator at room temperature for 24 hours.

The resulting

white crystals were collected on Whatman #1 filter paper in
a Buchner funnel under suction.

The mother liquor was then

reduced to half volume with a current of air and crystallization ·allowed to occur as described above.
_________ was____!'epeated_ un_!;:i._~ no

fur_!!!~:r'.-~_ry-sta.ls_

This procedure

:fo_r!Ile9-. _ '!'hj.n-_!_aJT~_r

chromatographic (TLC) analysis showed these crystals to
contain a mixture of lythrine, cryogenine and an unidentified
yellow pigment.
A

separat~on

procedure differing from the original

method of Blomster, et al. (2) was attempted based on preliminary analytical-scale experiments which gave selective
!.J

elution of lythrine and cryogenine by decreasing the benzene
to chloroform ratio in five percent increments.

At a 70:30

ratio of benzene to chloroform, a pure lythrine fraction
was eluted to exhaustion.

A further decrease in the benzene

to chloroform ratio (60:40) yielded a pure cryogenine fraction.

Both lythrine and cryogenine fractions were monitored

by TLC.

However, these results could not be duplicated when

attempted on a preparative scale, so the following high
pressure liquid chromatographic separation was developed.
Analytical samples of six Heimia alkaloids were dissolved ( 1. 0 mgjml) in methanol: methylene chloride ( 70:30).
Individual retention times were determined by injecting 10
microliters of the alkaloidal solutions onto a column using

H

F'
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a Rheodyne syringe-loading sample injector fitted with a
175-microliter sample loop.

The mobile phase (methanol:

methylene chloride 70:30) was filtered through a 0.22 micron
Millipore filter under suction and then pumped at a rate of
2.0 mljminute by a Perkin Elmer Series 2/1 HPLC.

Separa-

tion was accomplished using a Partisil SAX 10 analytical
He_i_mia_alkalo_ids _wer_e_ det e_c ted
with a Perkin Elmer LC-55 spectrophotometer set at 285
nanometers and monitored with an Omni-Scribe chart recorder.
The column was allowed to equilibrate for two hours prior
to use and all separations were performed at room temperature (72-75°F).

Retention times for the six Heimia alka-

loids are listed in Table III.
High pressure liquid chromatographic (HPLC) separation
of cryogenine and lythrine on a preparative scale was then
carried out as follows.

The mixed alkaloidal fraction ob-

tained by column chromatography and corresponding to "Fraction I" of Blomster, et al. ( 2) was dissolved in 1. 0 ml of
methanol:methylene chloride (70:30) and passed through a
Sep-Pak cartridge silica filter to remove any highly polar
and particulate principles.

The cartridge was flushed with

4.0 ml of solvent to insure complete elution of the alkaloids.
The filtrate was reduced to dryness by flash evaporation
at 40°C in vacuo then re-dissolved in 2.0 ml of methanol:
methylene chloride (70:30).

A 1.0 ml aliquot was injected

utilizing a Rheodyne sample injector fitted with a 1.1-ml
sample loop.

"'"""'''''

,

I

I

I

Table III.

Retention Times for Six Lythraceae Alkaloids Det~rmined by HPLC

Alkaloid a

Quantity, meg

Retention Time, sec.

Minor Peaks, sec.

Lythrine

10

100

40, 50

Lythridine

10

105

40, 600

Nesodine

10

115

40, 50

Lyfoline

10

170

40, 115,. 600

Sinicuichine

50

450

40, 50, 95; 125

Cryogenine

10

605

40, 140, 220, 415

aAll alkaloids used for analytical HPLC determinations were ~xtracted from
Heimia salicifolia by A. E. Schwarting and A. Rother at The !University of
Connecticut, Storrs CT.
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The mobile phase (methanol:methylene chloride 70:30)
was pumped at a rate of 3.0 ml/minute by a Perkin Elmer
Series 2/1 HPLC through a Whatman Partisil 10 SAX M-9
preparative column (9.4 mm

~

500 mm) and passed through a

Perkin Elmer LC-55 spectrophotometer set at 250 nanometers.
The fractions were monitored by a Houston Instrument Omni-

of 0.25 em/minute and collected in 4.0-ml fractions.

At a

sample concentration of 50 mgfml, the resolution of the
two alkaloidal peaks was quite distinctive.
of the peaks was determined by TLC.

Identification

Lythrine eluted well

in advance of cryogenine.
The cryogenine fractions collected from the apex of
its elution peak were combined and flash evaporated at
40°C in vacuo, leaving a white precipitate.

To insure that

the cryogenine was in the free-base form, this precipitate
was dissolved in 25 ml of 10 percent acetic acid and brought
to a pH 0f 9.0 by the drop-wise addition of 58 percent
ammonium hydroxide.

The basic aqueous solution was placed

in a glass separatory funnel and extracted with chloroform
until further additions of ·6hloroform tested negative for
cryogenine by TLC.

The chloroform fraction was then flash

evaporated at 40°C in vacuo leaving a white precipitate
which was dissolved in a minimum amount of boiling absolute
methanol, covered and placed overnight in a dark desiccator
at room temperature.

The resulting crystals were collected

20
on Whatman #1 filter paper using a Buchner funnel under suetion and washed three times with cold, absolute methanol.
The crystals were dried at room temperature in vacuo over
phosphorous pentoxide for 24 hours.

This method of isola-

tion yielded cryogenine base of high purity as determined
by melting point, two-dimensional TLC and infra-red
'--------s-pec-t~G-P-hG-tGme-tFy----.

----'I!he----1-y-t-h-r-i-ne----fract-ion-s --were -t-rea-t-ed-- in

the same manner with similar results.
Carrageenan Pedal Edema in the Rat. -- Four synthetic phenylquinolizidine compounds prepared by Dr. James Quick of Northeastern University (Figure 1) were screened in rats

for

potential anti-inflammatory activity using the carrageenan
pedal edema assay proposed by Winter, et al. (40) and modified by Van Arman, et al. (49) .

Adult, heal thy, Sprague-

Dawley derived male rats (150-170 g; Simonsen Laboratories,
Gilroy CA) were maintained in our laboratory for one week
after receipt with free access to Purina Laboratory Chow
and tap water.

Twenty-four hours prior to experimentation,

the animals were placed on fast (tap water ad libitum) and
housed in individual cages with wide-mesh screen floors to
prevent coproph.agy.

Thirty minutes prior to the carrageenan

injection, the animals were dosed in a random pattern with
either a test drug finely suspended in 0.25 percent agar
or the 0.25 percent agar dosing vehicle alone.

Oral admin-

istration was selected to avoid any parenteral "counterirritant"

Figure 1.

Synthetic Intermediates Prepared by Dr. James
B. Quick.

r

l

RR-5-2 .......... Octahydro-4-(3-hydroxy-4-methoxyphenyl)
-2H-quinolizin-2-one; m.p. = 138-140°
[Hexane~Benzene]; light tan-white; 1 g.

JB-1-0 .......... 4:..(2-bromo-4,5-dimethoxyphenyl)
-octahydro-2H-quinolizin-2-one; m.p.
136-1380 [Hexane]; light yellow-tan;
700 mg.

=

MM-1-0 .......... Octahydro-4-(3,4-dimethoxyphenyl)-2Hquinolizin-2-one; viscous liquid; golden
brown; 500 mg.

HR-1-0 .......... 3-(4-hydroxyphenyl)-propenoic acid
octahydro-4-(3-hydroxy-4-methoxyphenyl)
-2H-quinolizin-2-yl ester; viscous liquid;
light golden brown; 500 mg.

22
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effect which might modify the development of the pedal edema.
Five minutes before carrageenan injection, the volume of
the right hind paw was measured plethysmographically to a
line circumscribed just above the animals's tibio-carpal
joint.

At time zero, a subplantar injection of 0.1 ml

of 1.0 percent carrageenan in sterile 0.9 percent saline was
______mad~_in_th§___r_i_gllt_hindc:Raw_ut_i_lizing a_micr_omet_er syringe
with a 27-ga:uge 3/4-inch needle.

The control group received

an equivalent amount of sterile 0.9 percent saline.

Paw

volumes were determined as previously described at +5 and
+30 minutes and at half-hour intervals thereafter.

Tests

for significant inhibition of carrageenan-induced pedal
edema by the test compounds were made utilizing analysis of
vari~nce

statistical techniques.

Croton Oil Mouse Ear Edema Assay. -- The topical antiinflammatory activities of selected natural and synthetic
compounds were determined using the croton oil mouse ear
edema assay of Tonelli, et al. (46) as modified by Van Arman
(47).

Adult, healthy Swiss-Webster derived female mice

(17-20 g; Simonsen Laboratories, Gilroy CA) were housed in
our facilities for at least one week prior to use and given
Purina Laboratory Chow and tap water ad libitum.

One hour

prior to experimentation, the mice were randomly placed in
individual cages with wide-mesh screen floors to prevent
coprophagy and provided free access to food and tap water

24

for the remainder of the experiment.

Each mouse was anes-

thetized with ether and, upon loss of righting reflex, 0.1
ml of a solution containing 2 percent croton oil, 73 percent
ether, 20 percent pyridine and 5 percent double-distilled
water was applied in four aliquots using a 25-microliter
Eppendorf pipette (two applications to the anterior and two
-----~--

--t-o- the-posterior -surfaces of- each animal' s·right ~-ear}.One hour after the application of the croton oil solution, the individual test compounds were dissolved or suspended at concentrations containing the specified drug dose
in 0.1 ml of a vehicle consisting of 75 percent ether, 20
percent pyridine and 5 percent double-distilled water.
The mice were again anesthetized with ether and 0.1 ml of
drug solution/suspension applied to the right ear in the
manner previously described.

Vehicle alone was applied to

the ears of the control animals.
Th~ee

hours after the drug applications, the mice were

sacrificed with ether and both the right and left ears excised at the base.

A 8.0-mm circle of ear tissue was re-

moved with a size #4 cork borer, using the outer margin of
the

~ar

as a landmark in order to avoid the extra hair and

tissue found at the base of the ear.

The sections were

placed in marked spot-test plates to insure proper identification and then individually weighed to the nearest tenth of
a milligram on a Sartorius laboratory balance.
The increase in weight induced by croton oil was found

25

by subtracting the weight of the untreated left ear section
from that of the right ear section.

Drug effects (expres-

sed as percent inhibition) were determined by subtracting the
weight increase of treated individual ears from the mean
weight increase of the control group and the difference times
100 divided by the mean weight increase of the controls.
_______ Anal~siS_Q:f__ya:r_ian_ce_sta_tistLcal_t_echniques __were__used _to
determine the significance of any inhibition of the croton
oil-induced ear edema.

RESULTS
Carrageenan-Induced Rat Pedal Edema Assay. -- The subplantar injection of carrageenan resulted in the
teristic
Figure 2).

charac~

btphasic acute inflammatory response (Table IV,
Orally administered aspirin (400 mgjkg) sig-

nificantly (P < 0.05) inhibited the acute inflammatory reaction at all time intervals evaluated (Table IV).

Indo-

methacin given orally (12.5 mgjkg) displayed noticeable
anti-inflammatory activity; however, this activity became
significant (P < 0.05) only during the final half hour of
the five-hour evaluation (Table IV, Figure 3).

Indometha-

cin's lack of activity in suppressing the first phase of
carrageenan-induced pedal edema is well established (44);
however, its delayed onset during the present study may
be due, in part, to the interval between drug dosing and
carrageenan injection which was shortened by one-half hour
to facilitate the number of compounds evaluated.
26
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Table IV.

Effects of Seven Orally Administered Selected Drugs
on Carrageenin-induced Rat Pedal Edema

Mean

Parameter
------ ·--- ---· --whole-BodY----Weight, g

Injection
Control
(!! = 7)
--1-55-~-6+9~

(>

±1

r::

SEM

(Significance

---- ·- - -

o-:-5o)

159:-o+5~o--

(>

0.92+0.05
(> 0. 60)

0.89+0.02

0.88+0.03
(> 0. 70)

Paw Volume,
ml +5 min.

1. 08+0. 05

1. 08+0. 04

1. 06+0. 04

o. 90)

(>

---

0. 60)

Paw Volume,
ml, -5 min.

(>

~

Aspirin,
400 mg/kg
(!! = 10)

Carrageenin
Control
(!! = 10)

4--

Level

0. 70)

Volume Change
From +5 min

l!

~

+30 min, ml

-0.01+0.01
(< o-:-ool)*

+0.18+0.04

+0.05+0.3
(< o-:-o2)*

+60 min, ml

-0.05+0.02
(< o-:-ol)*

+0.32+0.08

+0.01+0.04
(< o-:-o5)*

+90 min, ml

-0.05+0.03
(< o-:-ol)*

+0.33+0.08

+0.11+0.04
(< o-:-o2)*

+120 min, ml.

-0.06+0.02
(< o-:-ool) *

+0.31+0.07

+0.09+0.04
(< o-:-o2)*

.+150 min, ml

-0.07+0.03
(< o-:-ool)*

+0.37+0.08

+0.12+0.04
(< o-:-ol)*

+180 min, ml

-0.05+0.02
(< o-:-ool)*

+0.43+0.08

+0.14+0.04
(< 0.01)*

+210 min, ml

-0.06+0.03
(< 0.001)*

+0.47+0.09

+0.17+0.05
(< 0.01)*

-------------------------

----

-- -

-----

--
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Carrageenin Control, P)a

Indomethacin,
12.5 mg/kg
(! = 10)

RR-5-2,
100 mg/kg
(~ = 10)

JB-1-0,
100 mg/kg
(N = 10)

______ lM. 0-1--5.3_. ___ -.-164.5-!-5. 0-- --160. 4+4. 9
(>

o:-8o)

(>

o:-7o)

(>

o:-8o)

HR-1-0,
100 mg/kg
(~ = 10)

MM-1~0

100 mg/kg
(N = 10)
___ ..a..v-r•vtJeJ
1 t=,/, ()-I..~ -~-

(>

o:-8o)

-

1 t=.O _?-l...t=. _/, __ -

-..~-vv•w•v•"""'

(>

o:-8o)

0.94±0.03
(> 0. 20)

0.97±0.05
o.lo)

0.86±0.03
(> 0. 40)

0.92±0.03
(> 0.40)

0.88±0.04
(> 0.80)

1.10+0. 03
(> 0.60)

1.14+0.05
(>
20)

o.

1.01+0.03

1.10+0.03

1. 05+0. 04

+0.14+0.03
(> o:-3o)

+0.19+0.05
(> o:-8o)

+0.10+0.02
(> o:-o5)

+0.18+0.02
(>
90)

+0.17+0.04
(> o:-8o)

+0.25+0.07
(> o:-4o)

+0.32+0.09
(> o-:-9o)

+0.17+0.03
(> 0. 05)

+0.33+0.04
(> 0.90)

+0.31+0.06
(> 0.90)

+0.27+0.07
(> o:-5o)

+0.30+0.08
(> 0. 70)

+0.19+0.03
(> o:-1o)

+0.40+0.05
(> 0.40)

+0.34+0.07
(> 0.90)

+0.29+0.07
(> 0.80)

+0.30+0.07
(> o-:-8o)

+0.20+0.03
(> o-:-10)

+0.40+0.05
(> o-:-3o)

+0.36+0.06
(> o:-6o)

+0.30+0.07
(> o-:-5o)

+0.32+0.06
(> o-:-6o)

+0.21+0.03
(> o":-o5)

+0.40+0.05
(> o:-7o)

+0.38+0.06
(> o:-8o)

+0.32+0.07
(> o:3o)

+0.38+0.07
(> o-:-6o)

+0.23+0.03
(< o-:-o5)*

+0.47+0.07
(> o-:-7o)

+0.42+0.06
(> o-:-9o)

+0.29+0.05
(> 0.10)

+0.42+0.09
(> o-:-7o)

+0.27+0.04
(< o-:-o5)*

+0.48+0.06
(> o-:-8o)

+0.47+0.07
(> o-:-9o)

e

(>

0.10)

(>

0.60)

o.

(>

0.50)

-

--- -- -

- - - - - - - - - - - - - - -----

- --- - - - - - - - - - - - - - - - -

--------- - - - - -

Table IV (continued)
Mean± 1 SEM

Parameter

Injection
Control
(.!'!_ = 7)

(Significance Level

Carrageenin
Control
(!'! = 10)

Aspirin,
400 mg/kg
(.!'!_ = 10)

+0.48+0.09

+0.13+0.05

Volume Change
-

--From--1-5-min--- ------------ __________ _

+240 min, m1

-0.06+0.03
(<

o:oOl)*

( <

o:ol)*

+270 min, ml

-0.05+0.03

+0.50+0.08

+0.12+0.05

+300 min, m1

-0.05+0.03

+0.51+0.08

+0.10+0.04

c< o:ool)*
(<

o:ool)*

c < o:ol)*
( <

o:ool)*

aAsterisks have been added to emphasize statistical significance.

=

i1
p

30

vs.

Carrageenin Control, P)

Indomethacin,
12.5 mg/kg
(N = 10)

a

RR-5-2,
100 mg/kg
(N = 10)

JB-1-0,
100 mg/kg
(N = 10)

MM-1-0
100 mg/kg
(1N = 10)

HR-1-0,
100 mg/kg
(N = 10)

--

+0.29+0.05
(> 0. 05)

+0.45±0.10
(> 0.80)

+0.29+0.04
(> 0.05)

+0.55±0.06
(> 0.50)

-

- - -- - - - - - -

+0.50±0.07
(> 0.80)
--

--

+0.27+0.05
(< 0.05)*

+0.46+0.10
(> o. 70)

+0.30+0.05
(> 0. 05)

+0.54+0.06
(> 0. 60)

+0.51+0.08
(> 0.90)

+0.25+0.06
(< 0.02*

+0.50+0.11
(> 0.90)

+0.33+0.05
(> 0.05)

+0.58±0.06
(> 0.40)

+0.52+0.07
(> 0.90)

l,,;,,fll''

Figure 2.

Time Course of Carrageenan-Induced Pedal Edema in

~he
I

Rat.

x ; Carrageenan Control

a ; Aspirin (400 mgjkg)
~

;

JB-1-0 (100 mgfkg)
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Figure 3.

Time Course of Carrageenan-Induced Pedal Edema in tlhe Rat.
x

=

o

= Indomethacin (12.5 mgfkg)

D.

= JB-1-0 (100 mg/kg)
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JB-1-0 showed significant (P < 0.05) anti-inflammatory
activity at times +180 through +210 minutes (Table IV,
Figure 2) when given orally at a dose of 100 mgjkg.

At

this dose level, a marked sedation was noted in all animals
screened.

This peculiar sedation, which began two hours

after the compound was administered and persisted throughout
the course of the experiment, is noteworthy since all prior
reports of the depressant and ataractic properties of
lythraceae alkaloids were achieved only when the compounds
were administered by

intraperiton~al

injection.

Three ad-

ditional synthetic phenylquinolizidines, RR-5-2 (Figure 4),
MM-1-0 (Figure 5) and HR-1-0 (Figure 6) were essentially
devoid of any real anti-inflammatory activity when given
orally at a dose of 100 mgjkg. --this dosage of cryogenine
will consistently suppress the second stage inflammatory
response of carrageenan pedal edema (11, 19, 21).
Croton Oil-Induced Mouse Ear Edema Assay.--The topical
application of croton oil produced a significant increase in
ear weight characterized by edema, hyperemia and an overall
increase in ear size.

Table V and Figures 7 - 9 depict the

dose-response data (8 mice per dose) used to calculate the
respective potencies and ID 50 (mgjear to produce the 50 percent suppression of edema) values that are summarized in
Table VI.

An assay l.ambda ( sjb) could not be calculated

for the assay of dexamethasone vs indomethacin since the

Figure 4.

Time Course of Carrageenan-Induced Pedal Edema in!the Rat.
x

=

Carrageenan Control

o = RR-5-2 (100 mgjkg)
~

= JB-1-0 (100 mgjkg)
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Figure 5.

Time Course of Carrageenan-Induced
Pedal Edema in!the Rat.
1
x

= Carrageenan Control

a = MM-1-0 (100 mgjkg)
~

= JB-1-0 (100 mgjkg)
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Figure 6.

Time Course of Carrageenan-Induced Pedal Edema inithe Rat.
x

= Carrageenan Control

a =
~

HR-1-0 (100 mgfkg)

= JB-1-0 (100 mgjkg)
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Drug Effects on Croton Oil-Induced Mouse Ear Edema

Mean Valuesl (SEH)
Treatment
Control

Drug
(mgjear)
0

I

Percent
Inhibition

Percent
Inflammati.on
I

N

11

Wt -W c
18.74 (0.84)

I

i

130.27 (5.!27)
I

0

I

Indomethacin

0.5

8

12.14 (1.56)

79.50 (10).36)

36.75 (7.13)

I

1.0

8

9.13 (1.11)

I

60. 00 ( 8 ..58)
I

51.13 (5.98)

i

2.0

8

5.08 (0.26)

35. 25 ( 1. :85)

73. 00 ( 1. 38)

2.0

8

11.81 (0. 70)

79.13 (5.173)

37.13 (3.71)

4.0

8

7.75 (1.24)

52 . 7 5 ( 8. ;36)

58.63 (6.58)

8.0

8

6.05 (0.84)

41.38 (5.94)

67.63 (4.43)

1.0

8

10.45 (1.06)

77.00 (8. 49)

44.25 (5.65)

2.0

8

6.19 (0.81)

48.50 (6.:83)

67.00 (4.35)

I

Phenylbutazone

Aspirin

Dexamethasone

1

I

4.0

8

3.08 (0.39)

22.88 (3./13)

83.63 (2.14)

0.0001

8

10.50 (0.98)

79.13 (8.;51)

44.13 (5.29)

0.001

8

8.04 (0.98)

64.75 (9.21)

57.38 (5.20)

0.01

8

4.68 (0.99)

38.00 (5./84)

73.13 (4.33)
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Table V.

Continued
I

Mean Values (SEM)
Treatment

Drug
(mgjear)

N

wt -w c

Percent I
Inflamma tj_on

Percent
Inhibition

I

j

I
I

Cryogenine

0.25

8

13.80 (2.07)

95.50 (14.!43)
I

I

31. 00 ( 8. 50)

:J

i

0.50

8

9.70 (1.23)

67.75 (8.B>7)

48.25 (6.56)
64;50 (8.61)

i

37.75 (7.34)

I

54.75 (4.51)

II

I

Lythrine

1.0

8

6.68 (1.61)

0.25

8

11.69 (1.38)

i

44.88 (9.77)
I
97.25 (11:.60)
I

II

i

0.50

8

8.46 (0.84)

69.75

1.0

8

5.61 (0.57)

49.13 (4.H3)

(7.~n)
I

70.00 (3.04)

II
•I

JB-1-0

p-Hydroxycinnamic acid

II

0.25

8

10.83 (1.20)

0.50

8

1.00

78.63 (8.82)

42.25 (6.39)

6.33 (1.12)

45.13

(7.~~6)

66.38 (6.00)

8

3.81 (0.55)

25.75 (3.97)

79.63 (2.93)

1.0

8

10.73 (1.24)

93.88 (8.!35)

42.75 (6.58)

2.0

8

7.90 (1.58)

79.63 (16!.2)

57.75 (8.46)

4.0

8

4.50 (0.87)

46.50 (9.,33)

76.00 (4.64)
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Figure 7.

Log Dose-Response Curve for Six Reference Compounds lin Regard
to the Suppression of Croton Oil-Induced Edema in Mice.
o = Dexamethasone
x = Chlorpromazine
~

=

Diphenhydramine

0=

Indomethacin

.lf~

=

Aspirin

=

Phenylbutazone
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Log Dose-Response Curve for Cryogenine, Lythrine, JB'-1-0
and Indomethacin in Regard to the Suppression of Cro 1ton
Oil-Induced Edema in Mice~
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Table VI.

....- .... -,~~~~~~-~-------------

Comparison of Test Compounds to Indomethacin in Supr1ressing
Croton Oil-Induced Ear ~dema in Mice
i
·
!
I

Lambda

Potency (95% C.L.)

Compound

ID

50

(mg)

IID

50

(umoles)

Molecular
Potencyb

I

-

1.0

Indomethacin

I

9.5xl0 -1

12.7

1.0

I

Dexamethasone

l7.80a

-

2.7xl0

Chlorpromazine

33.7 (20.9-54.6)

0.36

2.2xl0

Diphenhydramine

14.7 (9.7-21.9)

0.30

5.3xl0

-4

6.9xl0

-2
-2

7.lxl0

2.8 (1.4-2.9)

0.25

3.lxl0:-l

0.27

4.lxl0

-2

12.lxl0- 2

3900.0
38.0

I

I
I

JB-1-0

-4

8.4xl0

-1

12.9

II

3.2

I
I

Lythrine

2.0 (1.4-2.9)

-1

Cryogenine

1.6 (1.0-2.5)

0.33

5.5xl0 -1

Aspirin

0.8 (0.6-1.0)

0.23

1.2

9.4xl0
1

-1

2.7

1.3

2.1

:6.7

0.4

I
I

I
:I

p-Hydroxycinnamic acid

0.6 (0.4-0.9)

0.30

1.4

I

8.8

0.3

Phenylbutazone

0 . 4 ( 0 . 3- 0 . 6 )

0.27

3.0

I

9. 7

0.3

Cinnamic acid

0.1 (0.1-0.3)

0.38

a A lambda value and 95% C. L. for the potency
thedose-response curves are not parallel.

~Calculated from ID

i

50

:JlJmml1llrl'

I~

cannot: be calcul:a ted since
01

.......

estimate rather than potency.
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dose response slopes were not parallel; however the mean
lambda value for the remaining assays was 0.30.
'

It was possible to document dose-response curves that
would allow valid

rn 50 estimations for all compounds except

cinnamic acid for which the responses did not reach

40

percent inhibition -- a response considered as evidence
of effectiveness.

Kaplan, et al. (11) have shown this com-

pound to be ineffective orally against carrageenan-induced
pedal edema and adjuvant-induced polyarthritis in rats.

The

dose-response curve of dexamethasone was significantly flatter
than those of the other compounds.

This finding and its very

high potency would appear to place dexamethasone in a
separate pharmacologic class from the other agents tested.
Considering the relatively high molecular potencies obtained
for chlorpromazine and diphenhydramine, the croton oil ear
edema assay is not specific for anti-inflammatory compounds.
This observation is further substantiated by the ability of
ethacrynic acid, a potent diuretic, to be more active than
indomethacin in this assay yet devoid of any activity in the
carrageenan pedal edema assay (45).

---------------

----------·----

- ---- -

- ------- ----

-

---

DISCUSSION
)

Dr. James Quick of Northeastern University and the
Sheehan Institute of Research provided this laboratory with
the four synthetic quinolizidine compounds illustrated in
Figure 1.

Since these agents had not been screened pre-

viously for their anti-inflammatory capacity, it was important to establish whether any poss.essed significant activity against carrageenan-induced pedal edema.
The pathway to acute carrageenan-induced inflammation
has been delineated by Vinegar, et al. (50) and involves a
twelve-step process.

Edema formation is dependent on the

generation of a neutrophil chemotactic factor with a subsequent neutrophil migration followed by the in situ generation of a vasoactive prostaglandin intermediate which increases local capillary permeability.

Vane, et al. (51, 52)

demonstrated that the common non-steroidal anti-inflammatory
drugs inhibit prostaglandin synthetase and, moreover, that
a correlation exists between in vitro synthetase inhibition
53
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and in vitro anti-inflammatory activity.

Subsequent investi-

u

c-

gations (48) have implicated the highly-labile prostaglandin
intermediates as inflammo.gens since their biological
j

activity exceeds the

potency of the prostaglandins.

Of the four compounds evaluated, only JB-1-0 was effective at an oral dose of 100 mgjkg.

The capacity of

JB-1-0 to inhibit significantly the second stage of carrageenan-induced pedal edema is consistent with the activity
of cryogenine and several clinically-effective antiinflammatory agents; however, second-stage inhibition fails
to differentiate between peripheral and centrally-mediated
activity.

De Cato, et al. (19) found cryogenine's anti-

inflammatory capacity to be dependent on an intact pituitaryadrenal axis, although not affected by the central sedation
induced by phenobarbital.

Therefore, while the sedation

observed in the JB-1-0 treated animwls supports the drug's
ability to penetrate the blood-brain barrier, the extent to
which this involvement contributes to its anti-inflammatory
activity remains to be determined.

Since the molecular

weights of the four synthetic quinolizidines are roughly 0.85
times that of cryogenine, effectiveness at the 100 mgjkg dose
was considered to be a realistic criterion to be met if further testing was to be done.
t~d

Thus, only JB-1-0 was selec-

for additional screening.
The croton oil-induced mouse ear edema assay is an

accepted model of acute, localized edema useful in assessing

i"
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the antiphlogistic potential of topically-applied drugs.
The assay allows for concurrent assessment of systemic
percutaneous absorption, using thymus involution as an index of adreno-cortical activity.

Janoff, et al. (53) have

demonstrated marked microvascular damage with associated
functional changes after a single application of phorbol
myristate acetate (the active principle in croton oil) to
mouse ears .----Tlils-aam~Cge -t<f

~.l:fef

vascula_r_ emiothe-li urn- is

generally restricted to the venules and is accompanied by
an increase in mast cell degranulation; however, these
workers were unable to inhibit these acute inflammatory
changes by systemic pretreatment with chlorpheniramine, 2BOL (2-bromolysergic acid diethylamide) dibenzyline, hydrocortisone or aspirin.

These data suggest that while sys-

temic absorption of the drug substance following topical
application is probable, the effect.

of this absorption

is minor and any significant anti-inflammatory

acti~ity

must be initiated by the compound at the site of application.

Therefore, the inhibition of mouse ear edema induced

by croton oil reflects a compound's capacity to interact
with local vascular and cellular events that contribute to
the acute inflammatory response.
Four of the reference compounds selected for the croton
oil study are clinically useful anti-inflammatory agents.
While their capacities to suppress the manifestations of
acute and chronic inflammatory states run somewhat parallel,

- ----------------------- --===========
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their potencies and mechanisms of action vary with considerable complexity (54).
Dexamethasone, a synthetic steroid with high antiinflammatory and glucocorticoid activity, is the most potent
and has been shown to (i) inhibit alterations in vascular
tone and cap_illary permeability, ( ii) inhibit proliferation
of capillaries and fibroblast and collagen deposition, (iii)
stabilize lysosomal membranes, (iv) inhibit cellular metabolism, (v) inhibit the generation of kinins, (vi) inhibit
the responses of leukocytes and macrophages, (vii) inhibit
chemotaxis, (viii) alter the immune response and (ix) inhibit arachidonic acid generation from phospholipids.

The

croton oil-induced mouse ear edema assay displays a high
sensitivity for

topically~applied

steroids (46).

In the

present study, dexamethasone was found to be 1780 times
more potent than indomethacin.

This value is in agreement

with the work of prior investigators (46, 47) and suggests
that "high potency" is a restricted domain reserved for
steroids and allows for a presumptive determination regarding a test compound's corticoid-like activity.
Indomethacin, phenylbutazone and aspirin represent a
class of compounds collectively referred to as non-steroidal
anti-inflammatory agents (NSAI) and while each compound is
currently believed to exert its anti-inflammatory activity
by interfering with arachidonic acid metabolism, each possesses unique characteristic properties capable of inhibiting

'
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several of the events that mediate acute and chronic inflammatory responses.

Indomethacin has been shown to (i) inhibit

5-hydroxytryptophan decarboxylase, (ii) suppress kallikreininduced increases in permeability, (iii) uncouple oxidative
phosphorylation, (iv) inhibit mucopolysaccharide biosynthesis,
(v) inhibit ameboid motility of PMN leukocytes and (vi) react with selected serum and tissue proteins.

Aspirin and

phenylbutazone both have the capacity to (i) uncouple oxidative phosphorylation,. ( ii) stabilize lysosomal membranes,
(iii) inhibit synthesis of mucopolysaccharides.and (iv) inhibit histamine release.

However, aspirin also has been

found to interact with kinin formation and suppress antibody production and antigen-antibody reactions.

Furthermore,

the ability of sodium salicylate to suppress clinicallyestablished inflammation· while being relatively inactive
in inhibiting in vitro prostaglandin synthetase suggests
that no single mechanism of action can adequately account
for a drug's involvement with the dynamic inflammatory process.
The fact that cryogenine, lythrine and JB-1-0 all display similar dose-response profiles that closely parallel
those of indomethacin, aspirin and phenylbutazone would suggest that the lythraceae alkaloids do not possess significant
corticoid-like activity when applied topically.

However,

this would not rule out the capacity of these agents to
interact with the pituitary-adrenal axis upon systemic
administration.

rc=================~-

-

-~

58

Chlorpromazine has been shown to possess significant
antiphlogistic activity in the carrageenan pedal edema assay
(11).

While this drug's diverse pharmacological profile

suggests several potential mechanisms which may interact
with the inflammatory response (55), it remains ineffective
in the treatment of clinically-established inflammatory
disorders.

The present investigation determined chlorpro-

mazine to be 34 times more potent than indomethacin in
inhibiting the acute inflammatory response induced by croton
oil.

This impressive potency for a nonsteroidal agent sug-

gests that these two agents may differ in mechanism(s) of
action in this particular model of inflammation.

While

histamine plays a negligible role in the development of
carrageenan-induced rat pedal edema (50), its involvement
during the first two hours of croton oil-induced edema has
been established (53).

Chlorpromazine has antihistaminic

capability (56), and the fact that diphenhydramine, a
clinically-established antihistamine, was found to be 15
times more potent than indomethacin in the present study
indicates the relatively high activity of a histamine an+·
tagon±st in this particular inflammatory model.

The high

potency of chlorpromazine, when compared to diphenhydramine,
may be due to additional localized mechanisms which also
contribute to chlorpromazine's antiphlogistic capacity.
The documented antihistaminic pr0perties of crY,ogenine (13)
may play a role in suppressing croton oil-induced mouse ear

59

edema; however, its capacity to inhibit carrageenan- and
mycobacterium adjuvant-induced inflammations, where histamine involvement is insignificant, suggests a true antiinflammatory potential.
The test compounds evaluated in this study (cryogenine
lythrine, JB-1-0, cinnamic acid and para-hydroxycinnamic
acid) were selected with the intent of determining some of

---------:--t-he --s-t-ruc-t-u-r-a-1--Peq-u-i-!!emen-t-s -vJhich- account- -for --cryogenine !_g __
anti-inflammatory activity.

-----

Lythrine, the trans geometric

isomer of cryogenine, was selected to assess any potential
stereospecificity for molecular interactions with the hypothetical "cryogenine receptor."

The potencies of these

two alkaloids were found to be virtually identical; thus,
unlike indomethacin (57), no apparent stereospecific conformation is preferred.

This hypothesis is further supported

by the activity of JB-1-0, a racemic mixture, yet relatively
equipotent to cryogenine and lythrine.

Since cryogenine,

lythrine and JB-1-0 all have the same dimethoxy substitution
pattern on the phenyl ring, the importance of this region can
not be fully evaluated; however, it is noteworthy that of the
four synthetic compounds screened in the carrageenan pedal
edema assay, JB-1-0 was the only one which displayed significant activity.

The other three compounds are substituted

in the 3', 4', positions instead of the 4', 5', positions.
The possibility that steric hinderance occurs when the phenyl
ring is substituted in the 3' position deserves further evaluation.

60
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Since most of the clinically-effective anti-inflammatory
drugs are acidic molecules, it seems plausible to suspect
the cinnamic acid moeity of cryogenine and lythrine as the
active center for anti-inflammatory activity.

This idea is

supported by the findings of Weibelhaus, et al. (24) and
two brief reports (58, 59) describing the antiphlogistic
properties of cinnamic acid.

Kaplan, et al. (11) found cin-

--

-

-

---

-

namic acid to be devoid of any significant anti-inflammatory
activity against carrageenan-induced rat pedal edema.

While

the present study found cinnamic acid to be ineffective, its
para-hydroxy analog did elicit a measurable anti-inflammatory
response.

This analog more closely resembles the acidic

function found in the lythraceae alkaloids and this is noteworthy, since Van Arman (48) contends that phenolic compounds
inhibit inflammation by acting as radical scavengers,

Their

interaction with a highly reactive "hydroxy-radical" increases the net turnover of arachidonic acid resulting in
decreased local tissue levels of the highly reactive endoperoxides and the "hydroxy-radical"--both of which have been
linked to the inflammatory process.
( 24) imply tha't

lythrin~'

While Weibelhaus, et al.

s para-hydroxycinnamic moei ty is

essential for activity, the present study found JB-1-0 to
be equipotent to the two parent compounds.
Perhaps the most unique feature of the lythraceae alkaloid's anti-inflammatory capacity resides in the
fact that
,•.
they are nitrogenous bases.

Whitehouse (60) proposed that

---------- - - - - -

--

-----------
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the acidic nature of standard non-steroidal anti-inflammatory
drugs facilitates anionic binding to the lysyl E-amirro
groups of certain enzyme systems normally engaged in ATP
biosynthesis.

Scherrer (61) has described a similar recep-

tor consisting of a large flat area, a trough to accommodate
an out-of-plane group and a cationic site to accommodate
acidic anions or unprotonated amines.

While this model

conforms to the molecular makeup of indomethacin, aspirin
and phenylbutazone, it does not account for the antiinflammatory activity of cryogenine, lythrine and JB-1-0
which would remain highly protonated at physiological conditions.

Therefore, while the present study serves to help

delineate the active moeity of cryogenine and lythrine and
documents their topical anti-inflammatory activity (systemic
and topical activity were also determined for structurally
related JB-1-0), the exact mechanisms which account for the
antiphlogistic potential of these compounds still remain
to be determined.
Subsequent to the investigationsdiscussed here, a series
of four homologs of JB-1-0 were submitted to this laboratory
for investigation as a separate study.
results is included here as Appendix A.

A·report of the
The discovery that

SIR-92 exceeds the anti-inflammatory potency of JB-1-0 indicates that these compounds do indeed represent a fertile
area for

structure-acti~ity

research.
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Recently, Lema et.al. (62) in a preliminary study, found
cryogenine to inhibit the in vitro synthesis of prostaglandins,
displaying a dose-response profile very similar to the
clinically-established anti-inflammatories aspirin and
phenylbutazone.

Further investigation

of cryogenine's

effect on prostaglandin biosynthesis coupled with an evaluation of the drug's ability to modulate cyclic nucleotide
levels and alter neutrophil migration are indicated to determine whether cryogenine's unique chemical structure offers
any equally unique pharmacological approach for countering
the inflammatory process.
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-----~---~

-·

····--·---==----~-~======

CONCLUSION
Since prehistory, innumerable plant drug products have
undergone long-term "clinical trials" due to their ubiquitous employment as tribal medicinals and ritual drugs.

While

the reports of such use are subject to mythic distortion,
they direct the pharmacologist to plants with active principles whose a priori safety and efficacy warrant, at least,
some scientific evaluation.

The wide-spread use of Heimia

salicifolia as an ethnobotanical among the Indians of
Central and South America·suggests, if nothing more, a low
order of toxicity in man.

Since all the drugs currently

available in the United States for the treatment of rheumatoid arthritis and related inflammatory conditions have
undesirable side effects on chronic use, the lythraceae
alkaloids may represent a potentially safe, new pharmacologic
prototype with systemic and/or topical anti-inflammatory
activity.
Pre1iminary investigation of four synthetic phenyl63
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quinolizidines established that one of these compounds,
4-(2-bromo-4,5-dimethoxy phenyl) octahydro-2H-quino1izine2-one (JB-1-0), was capable of suppressing the inflammatory
response induced by the sub-plantar injection of carrageenan
in rats at an oral dose whi.ch is surely effective for cryogenine.
The topical anti-inflammatory potencies of cryogenine ·
- --------~ver-t~i-ne-)-anEl~l-y-t-hi'-i-ne-{both-isolated- from- Heimia salicifoliat -~
and JB-1-0 were determined using the method of Van Arman
(47).

When applied to the ears of female Swiss-Webster mice

one hour after the application of 2 percent croton oil,
potencies relative to indomethacin were, respectively:
1.59 (1.01-2.50)--95% confidence-limits, 2.04 (1.43-2.92),
and 2.82 (2.00-4.00).

Two structural components of the

natural alkaloids, para-hydroxycinnamic acid and cinnamic
acid, were less potent than indomethacin:
and 0.14 (0.01-0.03).

0.62 (0.41-0.93)

Other reference compounds included:

dexamethasone,· 1789 (837-3774,· estimated);

chlorp~omazine,

33.7 (20.9-54.6); diphenhydramine, 14.7 (9.7-21.9); aspirin,
0.76 (0.55-1.04); and phenylbutazone, 0.39 (0.27-0.56).

The

mean lambda value for these assays was 0.30; this value excludes the dexamethasone-indomethacin assay since these two
compounds have significantly different dose-response slopes.
In 1971, Chang and Malone (16) suggested that chemical
modification of cryogenine could result in a new class of
potent, nonsteroidal, anti-inflammatory agents.

In 1973,
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Weibelhaus, et al. (24) reported the alteration of lythrine's
anti-inflammatory and diuretic properties by chemical reduction of the cinnamic acid moeity to form decinine.

The

data in the present study suggest that the reactive component for anti-inflammatory activity resides within the
phenyl-quinolizidine portion of the lythraceae alkaloids
______r~1_h~_!'

_tl:!l!_n_j:h~_Q:i_nn_a.l!ll-~-~C?-:i-Q_po_rtiQ_n

and -tl:lat_ this

a<;_t~y_i~y____ _

is not stereospecific with respect to the quinolizidine
ring fusion.

Since bromide substitution of the phenyl ring

yields a compound (JB-1-0)- with significant anti-inflarrunatory
activity in two standard assays, further substitution of
the phenyl-quinolizidine ring system may well provide even
more potent anti-inflammatory agents.
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APPENDIX A
DATE:
TO:

April 14, 1981

Dr. James Quick
SISA Institute for Research Inc.
- -- ----- ----7Cl3D-COi1Cor-d--AVeillieCambridge, MA 02138

RE:

Report of Results of Anti-inflammatory Screening of Four Synthetic Compounds (SIR-85, SIR86, SIR-91, SIR-92) and Suitable Controls.
(Synthetic compounds Mailed by Dr. Quick to
Dr. Malone, October 17, 1980)

REF:

Notebook 25, pp. 229-236, 244-248.

Experimental.

Because of the very limited amounts of the

synthetics made available, the anti-inflammatory activity
was determined using the croton oil mouse ear edema assay
of Tonelli et al. (46) as modified by Van Arman (47).

This

assay has been shown by Byrne and Malone (63) to yield
positive results for lythraceae alkaloids and a chemically
related compound previously submitted to this laboratory
by Dr. Quick [4-(2-bromo-4, 5-dimethoxyphenyl)-octahydro-2Hquinolizin-2-one].
Adult, healthy, female Swiss-Webster derived mice
(17-20 g; Simonsen Laboratories, Gilroy CA) were housed in
our facilities for at least one week prior to use and maintained on Purina Lab Chow and tap water ad libitum.
71

One

72
hour prior to experimentation, the mice were randomly placed
in individual cages with wide-mesh screen floors to prevent
coprophagy and provided with free access to food and tap
water for the remainder of the experiment.

Each mouse was

anesthetized with ether USP and, upon loss of righting reflex, 0.1 ml of a mixture containing 2% croton oil, 73%
ether, 20% pyridine, and 5% double-distilled water was applied in four aliquots using a 25-microliter Eppendorf
pipette (two applications to the anterior and two to the
posterior surfaces of each animal's right ear).
One hour after the application of the croton oilcontaining vehicle, the i.ndividual test compounds were dissolved or suspended at concentrations containing the specific
drug dose in 0.1 ml of a vehicle consisting of· 75% ether,
20% pyridine and 5% double-distilled water.
again anesthetized with

eth~r

The mice were

USP and 0.1 ml. of drug-

containing solution/suspension applied to the right ear
in the manner previously described.

Drug-free vehicle was

applied to the right ears of the control animals.
Three hours after drug application, each mouse was
sacrificed with ether USP and both the right and left ears
excised at the base.

A 8.0-mm circle of ear tissue was

removed with a size #4 cork borer, using the outer margin
of the ear as a landmark in order to avoid the extra hair
and tissue associated with the base of the ear.

Each sec-

tion was individually placed in marked spot-test plates

73

to insure proper identification and then weighed to the
nearest tenth of a milligram using a Sartorius laboratory
balance.
The increase in weight induced by croton oil was found
by subtracting the weight of the untreated left ear from
that of the corresponding right ear.
ed

Drug effects (express-

as percent inhibition) were determined by subtracting

the weight increase of treated individual ears from the
mean weight increase of the control group and this difference (times 100) divided by the mean weight increase of
the controls. ,
The ID 50 values (the dose capable of reducing croton
oil-induced edema by 50 percent) and the potency estimates
relative to indomethacin as a standard were calculated mathusing regression methodology.

em~tically

Results are sum-

marized in Table VII.
Test Compounds.

The identity of the test compounds submitted

are noted in Figure 10 along with their "code names 11 for
this study.

Also tested was JB-1-0, since that compound

has been shown to be active using this technique (63).
Results.

We originally reported that JB-1-0 was active and

2.82 times the potency of indomethacin (63).

The present

data indicate a potency of 2.67 times indomethacin, which
figure is in very close agreement.

All four of the SIR com-

pounds were active and all somewhat more potent than

Figure 10.

Structures, Code Identification, and
Description of Submitted Compounds.
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H

SIR-85, very light canary yellow
(250 mg., m.p. 84-85, sol. dilute
acid, c H No , Batch 195.64 &
16 21 2
195.77)

---

~Ne-~-------------

~~~
A

O
I

~

,.

SIR-86, creamy white
(400 mg., m.p. 79-80, sol. dilute
acid, c16 H01No 2 , Batch 195.69 !i
195.72)
....

SIR-91, creamy white
(400 mg., m.p. 57.5-58.5,. sol.
dilute acid, c H25 No 3 , Batch
18
B-208.46)

SIR-92, white fine crystals
~mg., m.p. 130-131, sol. dilute
acid, c H No , Batch A~208.46)
18 25 3

llillillli''l
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Table VII.

Anti-inflammatory Effects Against Croton

Oil-Induce~i

Ear Edema in Mice

I

!.

Dose-Response
Slope, b
(Correlation
Coefficient, r)

D1se Reducing
!Edema 50%
I
ID5o•
mgjear

Compound

MgjEar

Mean Percent
Inhibition
+ 1 SEMa

Indomethacin

0.25
0.50
1.00

39.0 + 8.5
63.4 + 4.4
74.5 + 2.9

58.93 (0.68l)b

!0.352b

1.00

JB-1-0

0.25
0.50
1.00

62.2 + 6.4
69.3 + 4.4
85.4 + 2.2

38.52 (0.606)b

:o.132b

2.67

SIR-85

0.125
0.25
0.50

39.7 + 6.1
54.7 + 5.8
73.2 + 2.8

55.84 (o.709)b

:0.196b

1. 80

SIR-86

0.25
0.50
1.00

58.2 + 5.2
62.8 + 9.3
68.2 + 5.1

44.81 (0.525)c

!

0.164c

2.15

SIR-91

0.125
0.25
0.50

47 .{) + 7. 6
54.1 + 8.4
71.8 + 2.6

41.21 (0.491)b

io.163b

2.16

SIR-92

0.25
0.50
1.00

76.5 + 3.5
72.2 + 3.8
82.1 + 5.8

9.24 (0.193)d

J:o.107d

I

Potency

I

I

;.»-3. 29d

----~- ~~~-~-~~~~~----~---,=----------,il

Table VII.

Continued

aEight animals per test group.
Inhibition expressed relative ito a control (nondrug) group (N = 12) where mean edema formation was 18.59 mg (S.E.M. = 1.86).
bCalculated from regression equation where x
inhibition (arithmetic).

=

log dose per ear and y

=

percent

I

I

I

COnly two doses (0.25 and 0.50 mg) were submitted to regressi~n analysis, since
the response of the highest dose was clearly in the asymptotic section (active
response) of the dose-response curve.
I
I

I

dAll three doses are in the upper asymptotic section (active ~~esponse) of the
dose-response curve, so estimates of ID5o and potency were m:::_tde using graphical
means.
Lower doses would have been used on a subsequent day j, but initial testing
had consumed the entire 25 mg sample. The graphical estimate presumes that SIR92 will have a dose-response curve parallel to.that of indomethacin.

'I
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indomethacin, with SIR-85 being the least potent of the series,
SIR-86 and SIR-91 being essentially equipotent, and SIR-92
being the most potent and at least 3.29 times the potency
of indomethacin.

The activity of SIR-92 was clearly under-

estimated and all doses produced what can be termed as
"maximally effective" responses.

Testing a range of lower

doses was indicated, but the 25-mg sample had been completely
-----

consumed by the initial trials.

----

-

----------------

For a nonsteroidal compound,

the activity of SIR-92 is quite impressive.

